Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.67 |
| ▸ | HTR2B | P41595 | 4/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.59 |
| ▸ | HTR1A | P08908 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.48 |
| ▸ | TOP2A | P11388 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175157 | 1.00 | HTR2C (0.67) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| SCHEMBL3168067 | 1.00 | HTR2C (0.67) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL4124903 | 0.98 | HTR2C (0.65) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL4112913 | 0.98 | HTR2C (0.65) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| SCHEMBL15062038 | 0.90 | HTR2C (0.56) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| SCHEMBL1229562 | 0.89 | HRH1 (0.62) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL3467493 | 0.88 | HRH1 (0.60) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| Tert-Butyl Formate SCHEMBL28237168 | 0.86 | HTR2C (0.54) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| SCHEMBL26712584 | 0.85 | SLC6A2 (0.58) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 | |
| SCHEMBL8271831 | 0.83 | SLC6A2 (0.63) | HTR2CHTR2BSLC6A2HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822115-B2 | Nitrogen containing compounds and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-11-21 | — | — | US | disclosed |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| EP-2607364-A1 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | Ares Trading S.A. (CH) | 2013-06-26 | — | — | EP | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | HTR2C 761/4885HTR2B 268/4885SLC6A2 3049/4885 |
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | HTR2C 773/4885HTR2B 630/4885SLC6A2 218/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | HTR2C 773/4885HTR2B 630/4885SLC6A2 218/4885 |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NOS2, NOS1, NCF1 | HTR2C 4203/4885HTR2B 3540/4885SLC6A2 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.